Venous thromboembolism (VTE) is a frequent complication in patients with cancer. Homozygous carriers of the fibrinogen gamma gene have a moderately increased risk of VTE, but the effect of the variant in cancer is unknown. We aimed to investigate the effect of the variant and active cancer on the risk of VTE. Cases with incident VTE (n=640) and a randomly selected age-weighted sub-cohort (n=3,734) were derived from a population-based cohort (the Tromsø study). Cox-regression was used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for VTE according to categories of cancer and In those without cancer, homozygosity at the variant was associated with a 70% (HR 1.7, 95% CI: 1.2-2.3) increased risk of VTE compared to non-carriers. Cancer patients homozygous for the variant had a two-fold (HR 2.0, 95% CI: 1.1-3.6) higher risk of VTE than cancer patients without the variant. Moreover, the six-months cumulative incidence of VTE among cancer patients was 6.4% (95% CI: 3.5-11.6) in homozygous carriers of and 3.1% (95% CI: 2.3-4.7) in those without risk alleles. A synergistic effect was observed between and active cancer on the risk of VTE (synergy index: 1.81, 95% CI: 1.02-3.21, attributable proportion: 0.43, 95% CI: 0.11-0.74). In conclusion, homozygosity at the variant and active cancer yielded a synergistic effect on the risk of VTE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327659PMC
http://dx.doi.org/10.3324/haematol.2019.224279DOI Listing

Publication Analysis

Top Keywords

risk vte
24
active cancer
12
cancer patients
12
vte
10
cancer
10
fibrinogen gamma
8
gamma gene
8
risk
8
venous thromboembolism
8
homozygous carriers
8

Similar Publications

Background: Pediatric patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) are at an increased risk of arterial and venous thromboembolism (AVTE). Although the exact mechanisms underlying AVTE remain unclear, eosinophils play a pivotal role in AVTE.

Main Body: Current guidelines lack evidence-based recommendations, particularly concerning anticoagulant and antiplatelet treatments for this condition.

View Article and Find Full Text PDF

Background: Anticoagulants increase the risk of cardiac tamponade in patients with pericardial effusion (PE). Therefore, inappropriate administration of them in the presence of PE can lead to a catastrophic outcome. This study presents a patient with a provisional misdiagnosis of venous thromboembolism (VTE).

View Article and Find Full Text PDF

Purpose: Determine the rate of incidence, risk factors, and management for developing venous thromboembolism (VTE) in patients undergoing radiofrequency ablation (RFA) and ultrasound-guided foam sclerotherapy (UGFS) for varicose veins.

Methods: All charts of patients undergoing venous ablation from 2016 to 2023 were reviewed at a rural vein treatment clinic. The incidence of VTE was noted and a chart review was completed to identify risk factors for VTE, EHIT score, EFIT score, and management.

View Article and Find Full Text PDF

There are inconsistent results pertaining to risk factors for venous thromboembolism (VTE) in patients following urologic surgeries. We attempted to establish a visualization model to shed further light upon this topic. Consequently, a total of 436 patients who were tested for VTE following urologic surgeries were retrospectively enrolled.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) is the most feared complications of abdominoplasty, and multiple studies in the plastic surgery literature have sought to prevent these complications. General inhalational anesthesia can increase the risk of VTE via a variety of mechanisms. This study evaluates whether performing abdominoplasties under total intravenous anesthesia (TIVA) instead of general inhalational anesthesia can reduce the risk of VTE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!